Navigation Links
New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

n of TLR in small vessels (2.9 percent versus 4.8 percent in vessels less than 2.8 mm in diameter; p=0.046) compared to the Taxus Stent.

In the United States, the CYPHER(R) Stent is indicated for previously untreated lesions that are less than 30 mm in length with a reference vessel diameter ranging from more than 2.50 mm to less than 3.50 mm.

"Studies have shown that TLR is not benign. These registry findings provide additional assurance to the interventional cardiology community regarding the efficacy of the CYPHER(R) Stent to prevent the need for repeat revascularizations in a real-world clinical setting," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Cardiology Division of Cordis Corporation.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.

About Cord
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today that the ... company permission to conduct an open-label study of Antineoplastons ... age with a diffuse intrinsic brainstem glioma (DIPG). Study ... groups based on their age and whether or not ... study endpoint is a decrease in the size of ...
(Date:10/22/2014)...  Rescheduling of hydrocodone combination products (HCPs) will ... according to a new primary market research study ... research and consultation exclusively in the area of ... In August, the DEA ... from Schedule III to Schedule II status. This ...
(Date:10/22/2014)... BASKING RIDGE, N.J. , Oct. 22, 2014 ... (RMANJ), a world-renowned leader in the field ... more rapid approach to embryonic screening. The research ... American Society for Reproductive Medicine (ASRM) meeting in ... chromosome screening (CCS) and single gene defect (SGD) ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... 26, 2012  Richard Wolf Medical Instruments Corporation celebrates ... minimally invasive solutions that spare patients the costs ... (Logo:  http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) ... allowing doctors to visualize and access elusive sites ...
... April 26, 2012 - The Consumer Healthcare Products ... for signing into law House Bill 363, legislation ... implementing a drug offender registry, stricter penalties for ... stop-sale technology.  HB 363 and its companion legislation ...
Cached Medicine Technology:Richard Wolf Medical Instruments Corporation: 40 Years of Innovation 2
(Date:10/25/2014)... -- Arriving home safe and sound is one of the ... sure that costumes and goody bags have reflective strips that ... medicine doctor at Meadowlands Hospital Medical Center in Secaucus, N.J. ... should be flame-resistant, Davis said. He offers these others ... it on a small area of skin first to ensure ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... York, New York (PRWEB) October 25, 2014 ... transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed ... litigation underway in U.S. District Court, Southern District ... for Summary Judgment on Punitive Damages in a ... plaintiffs. In a ruling issued on October 21st, ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... herpes simplex -- might increase the risk of Alzheimer,s disease, ... a carrier of certain antibodies to the virus can double ... "The identification of a treatable cause [herpes simplex] of the ... Dr. Hugo Lovheim, an associate professor in the department of ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... , , , , ... on senior living communities, 43-year-old Steve Gurney, the founder and publisher ... a temporary resident of The Residences of Thomas Circle, a downtown ... on his blog www.everyoneisaging.com. , , During the ...
... , , WASHINGTON, Aug. 11 ... ZOOM-100DC brain electrical activity data collection system, has been cleared ... section 510(k) of the FD&C Act. The ZOOM-100DC is an ... and displaying EEG waveforms and providing conventional EEG measures displayed ...
... , , WILMINGTON, Mass., ... dermatology company that is developing and marketing Levulan((R)) Photodynamic Therapy (PDT) ... today its corporate highlights and financial results for the second quarter ... http://www.newscom.com/cgi-bin/prnh/20090810/D C 59366LOGO ) ...
... OF PRUSSIA, Pa., Aug. 11 At the CBI 3rd Annual ... announced the commercial release of CompleteSpend(TM) V2.5. CompleteSpend is the ... compliance needs. , , (Logo: ... , , Myriad state and pending federal laws ...
... Awarded $100,000 for Enhancing Health Care Delivery , , ... , , WASHINGTON , Aug. 11 Dr. ... his exceptional work to enhance health care delivery for hundreds of low income ... prize, named for Joseph H. Kanter, a pioneering advocate for electronic medical records, ...
... , , , , ... 2009 , PADRES Contra El Cancer (PADRES), a non-profit organization committed to improving ... the Spike for HOPE! Celebrity Volleyball match as part of the ... PRESENTED BY VIRGIN AMERICA . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090811/LA59829 ...
Cached Medicine News:Health News:Middle-Aged Senior Care Advocate to Move Into D.C. Retirement Community 2Health News:BrainScope(TM) Receives FDA Clearance for Portable EEG Device 2Health News:BrainScope(TM) Receives FDA Clearance for Portable EEG Device 3Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 2Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 3Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 4Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 5Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 6Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 7Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 8Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 9Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 10Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 11Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 12Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 13Health News:Health Market Science Announces Commercial Release of CompleteSpend V2.5 2Health News:Health Market Science Announces Commercial Release of CompleteSpend V2.5 3Health News:Dr. James O'Connell Named J.H. Kanter Prize Laureate 2Health News:Dr. James O'Connell Named J.H. Kanter Prize Laureate 3Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 2Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 3
... 8F Percutaneous Vascular Surgical (PVS) System consists of ... Perclose Knot Pusher. The Prostar XL 8F PVS ... two pairs of sutured needles as well as ... precisely control the needles during deployment. the Perclose ...
... The new solid-state IRIS Medical IQ ... the treatment of retinal disorders and ... represents its latest technological innovation and ... Minimum Intensity Photocoagulation (MIP) procedures in ...
... The AIA-360 is a sophisticated Aumated Immunoassay Analyzer ... analyzer has a footprint of 16 X 16 ... Its compact design is ideal for physician ... testing, such as cardiac panels, as well as ...
... Solitaire represents the latest in green laser ... for use in both the operating room ... preference testing and the most experienced ophthalmic ... is the premium 532nm photocoagulator - unique ...
Medicine Products: